KIT and gastrointestinal stromal tumor: Consistent with the knockout results, the phosphorylated KIT level was diminished in JQ1‐treated imatinib‐resistant GIST cells (Figure 5A), which was in line with the significantly decreased KIT mRNA levels (Figure 5B,C).